添加维生素D3治疗50例缓解复发型多发性硬化的研究

Supplement of vitamin D3clinical in treatment of 50 cases of relapsing remitting multiple sclerosis

目的探讨维生素D3添加治疗缓解复发型多发性硬化(RRMS)患者的临床疗效和安全性。方法将50例缓解复发型多发性硬化(RRMS)患者随机分成维生素D3组和激素组,每组各25例,维生素D3组在激素治疗的基础上添加骨化三醇胶丸口服,治疗前后检测外周血T细胞亚群CD4+、CD8+、CD4+/CD8+、Th1、Th2数量,评定NIHSS分值,观察并记录治疗期间药物的安全性及副作用。结果治疗前维生素D3组与激素组在年龄、病程、性别以及NIHSS评分比较差异无统计学意义(P>0.05),治疗后CD8+、CD4+/CD8+、Th2数与治疗前比较及治疗后2组间比较差异均无统计学意义(P>0.05),治疗后CD4+、Th1数、NIHSS评分与治疗前比较及治疗后2组间比较差异有统计学意义(P<0.05)。结论维生素D3添加治疗缓解复发型多发性硬化(RRMS)患者具有较好的临床疗效。

Objective To study the clinical efficacy and safety of vitamin D3 in patients with relapsing rematting multiple sclerosis （RRMS） by using clinical randomized controlled study. Methods 50 cases of relapsing remitting multiple sclerosis in patients with relief, were randomly divided into vitamin D3 group and prednisone group, 25 cases in each group, vitamin D3 group in the treatment of hormone based add calcitriol cap- sules. The lymphocyte subsets, CD8 ＋ , CD8 ＋ T, Thl, CD4 ＋/, CD4 ＋ , Th2, NIHSS scores were detec- ted, and the safety and side effects of the drugs during the treatment were evaluated. Results There was no significant difference between the treatment of vitamin D3 group and the hormone group in age, duration of disease, gender and NIHSS numerical （P〉0. 05）, there was no significant difference between before treatment and after treatment in CD8 ＋ and CD4 CD8 ＋ cells and Th2 numerical （P〉0. 05）, there was no signifi- cant difference between before treatment and after treatment in CD4 ＋ Thl, NIHSS score （P〈0. 05）. Conclusion vitamin D3 has good clinical effect in the treatment of RRMS, and can be used in clinic.